Ceramides and metabolic profiles of patients with acute coronary disease: a cross-sectional study

• DOI: 10.3389/fphys.2023.1177765
• Publication Date: 2023-12-11T18:30:48Z
• Authors: Liang Zhang; Dawei Tan; Yang Zhang; Yaodong Ding; Huiqing Liang; Gong Zhang; Zhijiang Xie; Nian Sun; Chunjing Wang; Bingxin Xiao; Hanzhong Zhang; Lin Li; Xiufeng Zhao; Yong Zeng
• Keywords: Cross-sectional study

Metabolic Syndrome (MS) is a rapidly growing medical problem worldwide and characterized by cluster of age-related metabolic risk factors. The presence MS increases the likelihood developing atherosclerosis significantly raises morbidity/mortality rate acute coronary syndrome (ACS) patients. Early detection crucial, biomarkers, particularly blood-based, play vital role in this process. This cross-sectional study focused on investigation certain plasma ceramides (Cer14:0, Cer16:0, Cer18:0, Cer20:0, Cer22:0, Cer24:1) as potential blood biomarkers for due to their previously documented dysregulated function A total 695 ACS patients were enrolled, with 286 diagnosed (ACS-MS) 409 without (ACS-nonMS) serving control group. Plasma ceramide concentrations measured LC-MS/MS assay analyzed through various statistical methods. results revealed that Cer24:1 correlated Upon further examination, Cer18:0 emerged promising biomarker early stratification, its concentration showed significant sensitivity minor changes status participants. observational was secondary analysis multicenter prospective cohort (Chinese Clinical Trial Registry, https://www.who.int/clinical-trials-registry-platform/network/primary-registries/chinese-clinical-trial-registry-(chictr) , ChiCTR-2200056697), conducted from April 2021 August 2022.